Tagged as: Biosimilars News

FDA Commissioner Gottlieb Gives Speech on Biosimilars

Earlier today, FDA Commissioner Scott Gottlieb, MD, gave a speech focusing on biosimilars at America’s Health Insurance Plans’ National Health Policy Conference in Washington, D.C.  In his speech, Commissioner Gottlieb highlighted a 2017 study by QuintilesIMS that observed significant cost savings and dramatically expanding patient access in the EU from biosimilars…

Read More

Association of Accessible Medicines: Ensuring the Future of Accessible Medicines in the U.S.

The Association of Accessible Medicines (“AAM”) released a white paper on avoiding shortages and ensuring drug competition for patients in America.  AAM is advocating for the uninterrupted availability of lower-cost generic and biosimilar medicines.  In the paper, AAM asserts that by placing biosimilar medicines on a level competitive playing field with…

Read More

Study Shows that Celltrion’s Infliximab Biosimilar is Comparable to Reference Infliximab and Adalimumab

According to a Celltrion press release, this week investigators presented twelve-month data from a UK-wide, three-year prospective observational study showing comparable efficacy between CT-P13 (Celltrion’s biosimilar infliximab), reference infliximab (Johnson and Johnson’s Remicade), and adalimumab (AbbVie’s Humira). The press release reports that the Personalised Anti-TNF therapy in Crohn’s disease Study…

Read More